Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2), SCD-044_High Dose (Dose 3)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Yuma, Arizona • Encino, California • Los Angeles, California + 20 more
Conditions
Psoriasis
Interventions
placebo, CT 327
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more
Conditions
Psoriasis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Conditions
Psoriasis Vulgaris, Topical Administration
Interventions
Total coumarin (TC) cream, Vehicle
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Conditions
Psoriasis, Obesity
Interventions
Adipose tissue biopsy (fat biopsy)
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
DMB-3115, Stelara
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Norman, Oklahoma • West Jordan, Utah
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, placebo to secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Conditions
Psoriasis
Interventions
CTA018 cream
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more
Conditions
Moderate to Severe Palmar Plantar Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Not applicable Interventional

Deucravacitinib Adherence Study

NCT05570955
Conditions
Psoriasis
Interventions
Text reminder
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Psoriatic Arthritis
Interventions
TILD sub-cutaneous (SC) injection
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
41
States / cities
Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more
Completed No phase listed Observational Accepts healthy volunteers

Premature Coronary Artery Disease (CAD) in Severe Psoriasis

NCT00893126
Conditions
Psoriasis, Coronary Artery Disease
Interventions
CCTA Scan (Coronary CT Angiogram)
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion, Vehicle Lotion, Vehicle Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Encinitas, California + 35 more
Conditions
Psoriasis, Atopic Dermatitis
Interventions
CT-100-004-A, CT-100-004-B
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriasis, Stress
Interventions
Transdermal Electrical Neuromodulator (TEN)
Device
Lead sponsor
Thync Global, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Fremont, California • San Diego, California • Santa Monica, California
Conditions
Psoriasis
Interventions
Secukinumab Auto-Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Psoriasis
Interventions
adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Conditions
Psoriatic Arthritis
Interventions
ATI-450, Placebo Oral Tablet
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Miami Lakes, Florida • Tampa, Florida • Freehold, New Jersey + 5 more
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Plaque Psoriasis
Interventions
TAK-279, Placebo, Apremilast
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 54 more
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Conditions
Moderate Plaque Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
45
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more